Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: Nat Microbiol. 2022 Oct 26;7(11):1906–1917. doi: 10.1038/s41564-022-01254-1

Figure 2: SARS-CoV-2 viral kinetics in the bamlanivimab 700mg treatment arm.

Figure 2:

SARS-CoV-2 viral loads from (A) Nasopharyngeal (NP) swabs (collected at day 0, 3, 7, 14, 21 and day 28) and (B) from anterior nasal (AN) swabs (collected daily through day 14 followed by day 21 and day 28) plotted against study day. Lines show median viral load. The lower limit of quantification was 2.0 log10 SARS-CoV-2 RNA copies/mL while the lower limit of detection was 1.0 log10 copies/mL. Viral loads between groups were compared at each time point using the two-sided Mann-Whitney U tests denoted by asterisks wherever significant. (NPH Day 0 P=0.0369, NPH Days 3, 7, 14 P<0.001, AN Day 0 P=0.0135, AN Day 1 P=0.0402, AN Day 2 P=0.0066, AN Day 3 P=0.0145, AN Day 4 P=0.0013, AN Days 5–8 P<0.001, AN Day 9 P=0.0018, AN Days 10–14 P<0.001).